Soleno Therapeutics Inc (NASDAQ: SLNO) on Friday, soared 6.93% from the previous trading day, before settling in for the closing price of $62.87. Within the past 52 weeks, SLNO’s price has moved between $36.61 and $74.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 39.57%. With a float of $36.40 million, this company’s outstanding shares have now reached $45.70 million.
In an organization with 92 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Soleno Therapeutics Inc (SLNO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Soleno Therapeutics Inc is 20.63%, while institutional ownership is 90.92%. The most recent insider transaction that took place on Apr 01 ’25, was worth 265,156. In this transaction an insider of this company sold 3,782 shares at a rate of $70.11, taking the stock ownership to the 27,036 shares. Before that another transaction happened on Apr 01 ’25, when Company’s Officer proposed sale 3,782 for $70.11, making the entire transaction worth $265,156.
Soleno Therapeutics Inc (SLNO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 39.57% per share during the next fiscal year.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
Soleno Therapeutics Inc (SLNO) is currently performing well based on its current performance indicators. A quick ratio of 15.68 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.26, a number that is poised to hit -0.89 in the next quarter and is forecasted to reach 0.18 in one year’s time.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
Let’s dig in a bit further. During the last 5-days, its volume was 2.14 million. That was better than the volume of 1.07 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 43.83%. Additionally, its Average True Range was 5.34.
During the past 100 days, Soleno Therapeutics Inc’s (SLNO) raw stochastic average was set at 79.17%, which indicates a significant increase from 73.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 164.39% in the past 14 days, which was higher than the 77.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $52.75, while its 200-day Moving Average is $50.14. However, in the short run, Soleno Therapeutics Inc’s stock first resistance to watch stands at $69.03. Second resistance stands at $70.83. The third major resistance level sits at $74.29. If the price goes on to break the first support level at $63.77, it is likely to go to the next support level at $60.31. The third support level lies at $58.51 if the price breaches the second support level.
Soleno Therapeutics Inc (NASDAQ: SLNO) Key Stats
Market capitalization of the company is 3.08 billion based on 45,857K outstanding shares. Right now, sales total 0 K and income totals -175,850 K. The company made 0 K in profit during its latest quarter, and -55,980 K in sales during its previous quarter.
